Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study

Journal of Infectious Diseases

Volumn 213, Issue 12, 2016, Pages 1906-1913

  Dodd, Lori E ^a   Proschan, Michael A ^a   Neuhaus, Jacqueline ^c   Koopmeiners, Joseph S ^c   Neaton, James ^c   Beigel, John D ^b   Barrett, Kevin ^a   Lane, Henry Clifford ^a   Davey, Richard T ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adaptive design; Bayesian design; Clinical trials; Ebola virus disease; Emerging infectious diseases

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL PROTOCOL; COMPUTER SIMULATION; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; GUINEA; HUMAN; LIBERIA; MEDICAL RESEARCH; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIERRA LEONE; AFRICA; CONTROLLED STUDY; METHODOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

AFRICA, WESTERN; BAYES THEOREM; COMPUTER SIMULATION; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; RESEARCH DESIGN;

EID: 84974653208     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw061     Document Type: Article

References (16)

1. WHO consultation on potential Ebola therapies and vaccines. http://apps. who. int/iris/bitstream/10665/136103/1/WHO-EVD-Meet-EMP-14. 1-eng. pdf ? ua=1. Accessed 2 March 2016.
2. Ethical considerations for use of unregistered interventions for Ebola viral disease. http://apps. who. int/iris/bitstream/10665/130997/1/WHO-HIS-KER-GHE-14. 1-eng. pdf?ua=1. Accessed 2 March 2016.
3. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014; 371:2092-100.
4. Ansumana R, Jacobsen KH, Sahr F, et al. Ebola in Freetown area, Sierra Leone-a case study of 581 patients. New Engl J Med 2014; 372:587-8.
5. Jahrling PB, Hensley LE, Barrett K, Lane HC, Davey RT. State-of-the-art workshops on medical countermeasures potentially available for human use following accidental exposures to Ebola virus. J Infect Dis 2015; 212(suppl 2):S84-90.
6. Royston P, Parmar MK, Qian W. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat in Med 2003; 22:2239-56.
7. Proschan MA, Dodd LE. A modest proposal for dropping poor arms in clinical trials. Stat Med 2014; 33:3241-52.
8. Nass SJ, Moses HL, Mendelsohn J, eds. Implementing a National Cancer Clinical Trials System for the 21st Century. Washington, D. C. : National Academies Press, 2013. http://www. nap. edu/read/18362/chapter/1.
9. English RA, Lebowitz Y, Giffin RB. Transforming Clinical Research in the United States. Washignton, D. C. : National Academies Press, 2010. http://www. nap. edu/ read/12900/chapter/1.
10. Rosas SR, Schouten JT, Dixon D, et al. Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials. Clin Trials 2014; 11:553-9.
11. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-56.
12. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971; 44:793-7.
13. Agresti A. A survey of exact inference for contingency tables. Stat Sci 1992; 7:131-53.
14. Cox E, Borio L, Temple B. Evaluating Ebola therapies-the case for RCTs. N Engl J Med 2014; 371:2350-1.
15. Cooper BS, Boni MF, Pan-ngum W, et al. Evaluating clinical trial designs for investigational treatments of Ebola virus disease. PLoS Med 2015; 12:e1001815.
16. Lindblade KA, Kateh F, Nagbe TK, et al. Decreased Ebola transmission after rapid response to outbreaks in remote areas, Liberia, 2014. Emerg Infect Dis 2015; 21:1800-7.